» Articles » PMID: 36805596

A Non-genetic Switch Triggers Alternative Telomere Lengthening and Cellular Immortalization in ATRX Deficient Cells

Overview
Journal Nat Commun
Specialty Biology
Date 2023 Feb 22
PMID 36805596
Authors
Affiliations
Soon will be listed here.
Abstract

Alternative Lengthening of Telomeres (ALT) is an aberrant DNA recombination pathway which grants replicative immortality to approximately 10% of all cancers. Despite this high prevalence of ALT in cancer, the mechanism and genetics by which cells activate this pathway remain incompletely understood. A major challenge in dissecting the events that initiate ALT is the extremely low frequency of ALT induction in human cell systems. Guided by the genetic lesions that have been associated with ALT from cancer sequencing studies, we genetically engineered primary human pluripotent stem cells to deterministically induce ALT upon differentiation. Using this genetically defined system, we demonstrate that disruption of the p53 and Rb pathways in combination with ATRX loss-of-function is sufficient to induce all hallmarks of ALT and results in functional immortalization in a cell type-specific manner. We further demonstrate that ALT can be induced in the presence of telomerase, is neither dependent on telomere shortening nor crisis, but is rather driven by continuous telomere instability triggered by the induction of differentiation in ATRX-deficient stem cells.

Citing Articles

Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens.

Laemmerer A, Lehmann C, Mayr L, Bruckner K, Gabler L, Senfter D Neuro Oncol. 2024; 27(3):811-827.

PMID: 39556024 PMC: 11889718. DOI: 10.1093/neuonc/noae228.


Neotelomeres and telomere-spanning chromosomal arm fusions in cancer genomes revealed by long-read sequencing.

Tan K, Slevin M, Leibowitz M, Garrity-Janger M, Shan J, Li H Cell Genom. 2024; 4(7):100588.

PMID: 38917803 PMC: 11293586. DOI: 10.1016/j.xgen.2024.100588.


Accelerating 3D genomics data analysis with Microcket.

Zhao Y, Yang M, Gong F, Pan Y, Hu M, Peng Q Commun Biol. 2024; 7(1):675.

PMID: 38824179 PMC: 11144199. DOI: 10.1038/s42003-024-06382-4.


BLM helicase unwinds lagging strand substrates to assemble the ALT telomere damage response.

Jiang H, Zhang T, Kaur H, Shi T, Krishnan A, Kwon Y Mol Cell. 2024; 84(9):1684-1698.e9.

PMID: 38593805 PMC: 11069441. DOI: 10.1016/j.molcel.2024.03.011.


Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas.

Waitkus M, Erman E, Reitman Z, Ashley D Neuro Oncol. 2024; 26(6):1012-1024.

PMID: 38285162 PMC: 11145458. DOI: 10.1093/neuonc/noae016.


References
1.
Soldner F, Hockemeyer D, Beard C, Gao Q, Bell G, Cook E . Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell. 2009; 136(5):964-77. PMC: 2787236. DOI: 10.1016/j.cell.2009.02.013. View

2.
Greider C, Blackburn E . The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell. 1987; 51(6):887-98. DOI: 10.1016/0092-8674(87)90576-9. View

3.
Danussi C, Bose P, Parthasarathy P, Silberman P, Van Arnam J, Vitucci M . Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. Nat Commun. 2018; 9(1):1057. PMC: 5849741. DOI: 10.1038/s41467-018-03476-6. View

4.
Verma P, Dilley R, Zhang T, Gyparaki M, Li Y, Greenberg R . RAD52 and SLX4 act nonepistatically to ensure telomere stability during alternative telomere lengthening. Genes Dev. 2019; 33(3-4):221-235. PMC: 6362809. DOI: 10.1101/gad.319723.118. View

5.
Chiba K, Johnson J, Vogan J, Wagner T, Boyle J, Hockemeyer D . Cancer-associated TERT promoter mutations abrogate telomerase silencing. Elife. 2015; 4. PMC: 4507476. DOI: 10.7554/eLife.07918. View